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 3 
Abstract 4 
The lack of reproducibility of published studies is one of the major issues facing the scientific 5 
community, and the field of biofilm microbiology has been no exception. One effective 6 
strategy against this multifaceted problem is the use of minimum information guidelines. This 7 
strategy provides a guide for authors and reviewers on the necessary information that a 8 
manuscript should include for the experiments in a study to be clearly interpreted and 9 
independently reproduced. As a result of several discussions between international groups 10 
working in the area of biofilms, we present a guideline for the spectrophotometric and 11 
fluorometric assessment of biofilm formation in microplates. This guideline has been divided 12 
into 5 main sections, each presenting a comprehensive set of recommendations. The intention 13 
of the minimum information guideline is to improve the quality of scientific communication 14 
that will augment interlaboratory reproducibility in biofilm microplate assays.  15 
Keywords  16 
Biofilm, reproducibility, guidelines, microplate, spectrophotometry, fluorometry  17 
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 24 
Introduction 25 
A major challenge facing science today is the lack of reproducibility between published 26 
studies.1,2 Many factors contribute to this phenomenon, including the selective or insufficient 27 
reporting of experimental details in the published literature,  either in the methodology or 28 
data processing, that are essential for conducting the experiment.3 Furthermore, due to the 29 
rapid development of science, new terms are often introduced, or existing terminology is 30 
repurposed, which can create confusion when trying to understand a paper or reproduce a 31 
study.4  32 
Minimum information guidelines are an effective strategy for addressing the reproducibility 33 
crisis.5 These guidelines instruct authors and reviewers on the minimum information required 34 
for the experiments to be reproducible and the data to be comparable. They also allow the 35 
scientific community to standardise terminology leading to the development of ontology 36 
databases. However, they do not offer any information on whether a method is appropriate 37 
for a certain study nor endorse any specific protocols.  The Minimum Information for 38 
Biological and Biomedical Investigations (MIBBI) Project is a web based platform 39 
(www.mibbi.org) that gathers different minimum information guidelines in the biological and 40 
biomedical field, as well as any databases or standard ontologies related to them.4  41 
Minimum information about a biofilm experiment (MIABiE) (www.miabie.org) is one of the 42 
guidelines presented in MIBBI.6 It offers a broad view of the information necessary when 43 
conducting experiments related to biofilms. Biofilms are defined as a community of 44 
microorganisms embedded in an extracellular polymeric substance, often attached to a biotic 45 
or abiotic surface, which are essential in certain ecosystems but can also have detrimental 46 
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effects in industry and healthcare.7 MIABiE includes several modules, each addressing 47 
specific parts of a biofilm study, and presents an initiative for a biofilm ontology guide.  48 
The present guideline will expand some of the MIABiE modules by focusing on 49 
spectrophotometric and fluorometric methods of biofilm assessment in microplate 50 
experiments. These are widely used biofilm assessment methods due to their versatile 51 
applications in medical, industrial and environmental biofilm research.8  They can serve as a 52 
generic test, which does not require overly specialised or expensive equipment or training, 53 
and can generate high-throughput data because they are microplate compatible.  54 
Although several options for photometric or fluorescence-based methods in microplates exist, 55 
this guideline will focus on those methods most frequently used. This includes 56 
spectrophotometric methods used to quantify total biofilm mass based on the binding of dyes, 57 
such as crystal violet and safranin to cells and negatively-charged molecules (such as 58 
polysaccharides) in the biofilm matrix.9–11 Additionally, the guideline is applicable to 59 
fluorometric (or fluorescence-based) methods used to quantify the metabolic activity of cells 60 
within a biofilm, including those based on resazurin (also known as alamarBlueTM), 61 
fluorescein diacetate (FDA) and various tetrazolium salts like 2,3-bis-(2-methoxy-4-nitro-5-62 
sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT), 2-(4,5-dimethyl-2-thiazolyl)-3,5-63 
diphenyl-2H-tetrazolium bromide (MTT) and 2,3,5-triphenyl-tetrazolium chloride (TTC).8,12–64 
15
 Furthermore, methods that stain specific biofilm components such as SYTO 9, which stains 65 
nucleic acids 8,16, and Wheat Germ Agglutinin (WGA), which stains the extracellular 66 
polymeric substances (EPS), are also compatible with the guideline.17 67 
The Guideline   68 
This guideline focuses on spectrophotometric and fluorometric measurement of biofilm 69 
grown in microplates and is divided into 5 different sections labelled 01-05 (Figure 1). 70 
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Although there may be minor differences between staining reagents and techniques, this 71 
outline is designed to follow the chronological order in which the assays are typically 72 
performed and described. Section 01 pertains to the experimental design. Here the 73 
investigators determine the research question and how they may answer it. Once the 74 
experiment is mapped out, the next step is to grow the biofilm (section 02). This step includes 75 
inoculum preparation as well as biofilm growth in the microplate. Subsequently the biofilm is 76 
typically quantified or assessed using a specific stain and this biofilm assessment method is 77 
detailed in section 03. This process allows for minor variations depending on the target and 78 
the stain; however, the main steps are generally the same: washing, drying, staining, elution 79 
of stain and/or measuring absorbance or fluorescence (Figure 1). Once the reading is 80 
concluded and the data are collected, the next step is to analyse them (04). Moreover, in the 81 
interest of data sharing and communication we propose that data should be submitted to 82 
biofilm databases in the future (05). 83 
While developing the guideline, it became clear that methodological details that may be 84 
essential to achieve reproducibility of a biofilm experiment are often lacking critical 85 
information or omitted entirely. Therefore, in Table 1 we describe the most common 86 
omissions in reporting microplate methods and reflect on the potential impact of these 87 
omissions on the outcome of the experiment. At the end of each section of the guideline, we 88 
provide an example of a hypothetical simple experiment related to biofilm formation using 89 
crystal violet.  An example of similar guidance for a more complex analysis, involving the 90 
effect of antibiotic exposure on biofilms, can be found as supplementary information (Table 91 
S1). Additionally, it was of vital importance to gather a group of international researchers 92 
actively working in the area of biofilms in order to provide a balanced view on what can 93 
realistically be requested of most groups reporting these methods. All researchers involved in 94 
the process are listed as authors in this article. 95 
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01. Experimental design  96 
 97 
1. Describe the main question to be addressed in the study. This includes proposed main 98 
(and possibly secondary) hypothesis(es).  99 
2. Explain the experimental design for the study, in other words, what type of experiment is 100 
being conducted to test the hypothesis (es)? For example, a comparison between different 101 
treatments or factors; different microbial bacterial strains (i.e. reference “type” strains, 102 
mutant constructs or clinical isolates) or different concentrations and exposure times?   103 
3. State the number of biological replicates, meaning independent repeats of the same 104 
experiment. Ideally, these should be day-to-day replicates to account for changes in 105 
humidity and room temperatures, for example.  Include the number of technical replicates 106 
within the experiment, meaning the number of replicates for each sample group in the 107 
experiment. If applicable state whether the technical replicates are within one plate or in 108 
separate ones.  109 
4. Include the number of replicates for the controls used in the experiment.  Additionally, 110 
describe what these controls were and report their data to improve overall understanding 111 
of results. Depending on the test hypothesis they could be very straightforward, such as a 112 
growth check as a positive control and a sterility check as a negative control. On the other 113 
hand, they could be more complex. For example, if an antimicrobial agent is added and 114 
then rinsed off, an appropriate control is to use a mock carrier (e.g. saline) which accounts 115 
for the removal of microbes resulting from the exchange of fluids. Other appropriate 116 
controls for antimicrobial testing include solvent controls (e.g. DMSO) to verify that 117 
decrease in biofilm is due to the compound and not the solvent, and pre-treatment 118 
controls to verify that the effects observed are due to bactericidal not bacteriostatic 119 
activity. Furthermore, when biocide tests are performed it is recommended to perform a 120 
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neutralizer verification, as well as checking for interactions between the microplate 121 
material, biocide (e.g. bleach) and dye. It should be noted that controls are highly 122 
dependent on the experimental design, therefore it is important to report all the relevant 123 
controls.  124 
5. When applicable, provide reference to all published protocols followed, ideally to the 125 
original articles containing all the necessary information. Additionally, if any changes 126 
were made to these published protocols they need to be described in detail.  127 
6. Provide a link to any supplementary information or data not reported in the main body of 128 
the article, such as more detailed method descriptions, a metadata sheet containing raw 129 
data and layouts of microplate designs, etc.  130 
 131 
“This study investigated the effect of growth media concentration on Staphylococcus aureus 132 
biofilm formation in a microplate. Total biofilm mass formation after 24 hours for four 133 
different concentrations of Tryptic Soy Broth (TSB) was compared. Each experiment 134 
consisted of one plate that used 6 sample wells per TSB concentration, and 6 negative control 135 
wells containing only TSB for all four concentrations tested. Each experiment was repeated 136 
in three independent weeks. A more detailed description of the methodology together with a 137 
schematic illustration of the sample and negative control positions within the plate can be 138 
found in our supplementary data section [Link].” 139 
 140 
02. Biofilm formation  141 
 142 
1. Describe the microorganisms selected for the experiment. List the species and strain 143 
number, and if available the strain numbers assigned in international culture collections, 144 
e.g. ATCC, BCCM/LMG bacteria Collection, or DSMZ, or provide a reference in which 145 
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the relevant details of the strains are reported. Alternatively, if clinical or environmental 146 
isolates are used, provide all available and relevant background and ethical information. 147 
Describe the stock preservation conditions, and any modifications made to the 148 
microorganism (plasmid insertions, gene knockouts, etc) using established genetic 149 
nomenclature.   150 
2. Describe the inoculum preparation protocol. Include information on incubation conditions 151 
such as concentration, growth phase, temperature, time, shaking (rpm and orbital 152 
diameter or static conditions) and growth media (ingredients, concentration, origin). 153 
Depending on the microorganism, include other applicable incubation conditions such as 154 
light, CO2 concentration, humidity, etc.  Additionally, if any washing steps were 155 
performed include detailed information on centrifugation conditions (g force, time, 156 
equipment) and the washing agent used (water, PBS, etc). Other important factors might 157 
be whether a culture was grown up then diluted to a specific concentration, and how this 158 
was measured, i.e. optical density is commonly used. 159 
3. Describe the compounds or conditions being tested. In case of antimicrobials, describe 160 
their concentration (molarity, g/L or any other appropriate SI units), origin 161 
(manufacturers if purchased and catalogue numbers if allowed by the journal of choice), 162 
and time point in the experiment when they were added, and whether an agent was used 163 
to neutralize the active ingredient. If applicable, describe pH, any solvents used, activity 164 
corrections and whether agents were filtered prior to use.  165 
4. Provide information on microplates used. This includes type of plate (clear, white or 166 
black), number of wells (6, 9, 24, 96 or 384 well), shape of the wells (flat, rounded, U-167 
shaped or V-shaped), the material and the manufacturing company, including catalogue 168 
numbers if allowed by the journal of choice. Report any modifications made to the 169 
manufactured microplate such as pre-coating of the wells or addition of coupons.  170 
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5. Describe how the microplate was prepared. Provide information on the inoculum 171 
conditions at harvest such as growth phase, optical density (wavelength, zero solution, 172 
equipment) and concentration of microorganism (CFU/mL for bacteria or cells/mL for 173 
yeast) and growth media (if different from point 2).  If a biofilm prevention experiment is 174 
being conducted provide information on the antibiofilm agent used (concentration in 175 
relevant SI units, preparation and origin).  176 
If possible, provide a short description of the layout of the microplate showing the 177 
position of controls and samples. Additionally, if applicable mention any extra steps taken 178 
such as adding water to the outer wells to avoid “edge effects”.  179 
6. Provide a description of incubation conditions for the microplate. Include information on 180 
temperature, time and shaking (rpm and orbital diameter or stationary). Similar to point 2 181 
include a description of any other relevant conditions such as light, CO2 concentration or 182 
humidity. Additionally, if applicable mention any extra steps such as sealing the plate 183 
with parafilm or other films or incubating within a humidified container.  184 
 185 
“Staphylococcus aureus strain ATCC 25923TM was used. To prepare the inoculum, -80 °C 186 
glycerol stocks were streaked out on Tryptic Soy Agar [Manufacturer] plates. One colony 187 
from the plate was transferred into 15 ml TSB and incubated at 37 °C, 125 rpm in a shaker 188 
incubator [Model number] with an orbital diameter of 1.9 cm. After 18 hours a 1:100 189 
dilution of the inoculum was incubated at 37 °C, 125 rpm until it reached the exponential 190 
growth phase (OD=0.300 [595nm; Model number]). Four 2 ml aliquots of the suspension 191 
were made and washed by centrifugation (2000 g for 15 minutes [Model number]) and 192 
resuspending the pellets in PBS [pH 7.4; Manufacturer] twice. Subsequently, the pellets were 193 
resuspended in 4 different TSB broths (30 g/ml, 3 g/ml, 0.3 g/ml and 0.03 g/ml) and 200 µl 194 
per well of each of these suspensions was added to a flat bottom polystyrene 96 well plate 195 
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[Manufacturer] according to the layout in the supplementary data. The plate was incubated 196 
at 37 °C under static conditions in a non-humidified incubator for 24 hours. To prevent 197 
excess drying the outer wells were filled with 200 µl/well of sterile water.”  198 
 199 
03. Biofilm assessment method  200 
 201 
1. Describe the method followed to discard the planktonic suspension, e.g. pipetting, suction 202 
manifold.  203 
2. Describe all washing steps in detail. Provide information on the washing agent such as 204 
sterility, origin, concentration and pH, if applicable. Additionally, describe the number of 205 
washes and method(s) used to add and remove the washing agent (immersion, rinsing or 206 
pipetting). When possible, avoid the sole use of vague terms such as “gently” which are 207 
subject to interpretation and include more detailed descriptions. For example, describing 208 
the angle and depth at which a pipette tip was inserted into the well or stating the number 209 
of times the plate was shaken to remove excess liquid when inverted. If automatic liquid 210 
handling devices are used provide information of equipment and settings.  211 
3. Describe the staining process.  This includes information on the stain: origin 212 
(manufacturer), stock and working solution concentrations, solvents used as well as 213 
information on the staining: time and incubation conditions (light, temperature, volumes, 214 
shaking etc.). If applicable, provide information on any standard curves performed with 215 
the experiment.  216 
4. In cases where extra steps such as fixation, drying and elution are required, describe how 217 
these were performed and any solvents or chemicals (origin, concentration) used.   218 
5. Describe how the spectrophotometric or fluorometric signal was measured. Provide 219 
information on the equipment (model number, company, software) used as well as its 220 
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settings (excitation, emission and detection wavelengths, end-point or continuous read, 221 
shaking). When using fluorometric reading, provide information on the type of readout 222 
(top or bottom reading). If bottom reading is performed, provide information on the 223 
number and distribution of the points measured across each well.  224 
Furthermore, if imaging functions of the microplate reader were used, describe the 225 
settings (time, shaking, imaging mode, filters, camera).   226 
 227 
“The planktonic suspension was carefully removed using a multichannel pipette [Model, 228 
Manufacturer] fitted with a 300 µL tip inserted slowly at a 45° angle while making sure to 229 
avoid touching the sides and bottom of the wells. The plate was washed twice with 250 230 
µl/well of PBS using a multichannel pipette fitted with a 300 µL tip and left to air-dry for 15 231 
min in under laminar flow at room temperature (RT, 20 ±5 °C). The biofilm was fixed for 15 232 
min with 200 µl/well of 99% v/v ethanol [Manufacturer] and then allowed to air-dry until 233 
fully dry, between 5 and 10 minutes. The plate was stained with 200 µL of 0.1 % v/v Crystal 234 
violet [Manufacturer] for 15 min at RT, under static conditions. After staining the plates 235 
were washed twice with 250 µl/well of MilliQ water using a multichannel pipette and left to 236 
air-dry for 15 min in laminar flow. The stain was eluted with 200 µl/well of 99% v/v ethanol 237 
for 30 min at RT, no shaking. The eluted stain was mixed by pipetting up and down 4 times 238 
and 100 µl/well of it were transferred to an empty 96-well plate using a multichannel pipette. 239 
The absorbance was measured at 595 nm using a [Company; Model number] plate reader.” 240 
 241 
04. Statistical assessment and data presentation  242 
 243 
1. Describe how the raw data were processed and/or transformed. If possible, include raw 244 
data in the supplementary data section.  245 
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2. Present all outliers. Argumentation should be given if they were removed from the 246 
analysis in the results and ideally how their removal affected the data.  247 
3. Test the data for normality. Report if the data has been transformed or normalised for 248 
example, using a standard curve, log transformation, square root or any other appropriate 249 
normalisation method.  250 
4. Describe statistical tests and rationale for use (i.e. parametric, non-parametric, small 251 
sample, paired etc.) performed and any post-hoc tests. Provide information on the test 252 
parameters, descriptive statistics such as significant differences, standard errors, standard 253 
deviation, variance and confidence intervals. Additionally, include descriptive statistics 254 
for the controls used in the experiment.  If a high-throughput screening assay is being 255 
reported, it is recommended to include the calculation of the screening windows 256 
coefficient, or Z’. 18  257 
5. Ensure that the appropriate graph types and data visualizations are used. Figures should 258 
provide all the essential and relevant information necessary for a full understanding of the 259 
results.19 We suggest the use of scatter plots or box and whisker plots instead of line 260 
graphs or bar charts, which often do not portray all the necessary information in a dataset 261 
(Figure 2). For instance, many different normal, skewed or bimodal data distributions can 262 
lead to the same mean and standard deviation values. 19 Summarizing data as a mean with 263 
standard deviation can also conceal unequal sample sizes and outliers. 19,20 Plotting all 264 
measurements in tandem with means and standard deviations provides transparency and 265 
allows readers to evaluate data for themselves (Figure 2). 266 
6. Provide details of the statistical package used and its version. If more than one was used, 267 
they all need to be mentioned. Additionally, if any open source systems such as R 268 
packages were used, provide a reference or a link to it.  269 
 270 
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“Raw absorbance data can be found in our supplementary data section. To evaluate the 271 
within plate variability, the mean ± 1 standard deviation (STDEV) of all the technical 272 
replicates for each sample were calculated and are summarised in table [1]. The means of all 273 
the different samples were corrected by subtracting the corresponding negative control (TSB 274 
only) values. The data from all three replicate experiments were analysed using a one-way 275 
ANOVA test with a Levene’s post-hoc analysis to compare the absorbance values. These 276 
results were represented in Figure 1 and a more detailed description can be found in the 277 
figure legend. [Statistical Programme; version] was used to perform all tests.” 278 
 279 
05. Bioinformatics (Optional)  280 
 281 
1. Use standard terminology. In the coming years ontology guidelines for biofilm 282 
terminology are expected to be developed. A starting guide can be found on the 283 
MIABiE website.21    284 
2. The data should be formatted in a way that makes it easier to submit and extrapolate it 285 
to existing databases such as BiofOmics (http://www.biofomics.org/) or other 286 
databases currently in development.22   287 
As illustrated above, the amount of information necessary to fully characterize a complex 288 
system such as a biofilm experiment is significant. Therefore, a simplified checklist of the 289 
guideline has been included in this paper (Table 2). This checklist can assist authors during 290 
their writing process as well as reviewers during the peer-review process. In fact, 291 
complementary fields such as ecology and evolution have very recently started to make 292 
checklists available in their field of knowledge.23 Moreover, certain sections of this guideline 293 
can be applied to other biofilm assessment methods in microplate experiments, such as when 294 
viable plate counts are used to assess biofilm density and treatment efficacy. 295 
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Discussion 296 
Microplate-based spectrophotometric and fluorometric methods of biofilm assessment have 297 
led to the generation of a vast amount of data throughout the years. However, while these 298 
data have provided essential information on biofilm biology and experimental therapeutic 299 
strategies to tackle biofilms, biofilm experiments have often been difficult to reproduce.  300 
Furthermore, most of the time it is not possible to compare data between studies, which 301 
means that attempting to draw conclusions by combining data from different studies is not 302 
feasible. To minimize this problem, we suggest that a minimum information guideline should 303 
be adopted by researchers.  304 
Lack of data comparability can in part be attributed to the high variability of protocols used 305 
for these types of methods. Table 3 illustrates this phenomenon of variability in protocols of 306 
the crystal violet assay for three common organisms: Staphylococcus aureus, Pseudomonas 307 
aeruginosa and Candida albicans. It contains the range of parameters (low to high) for 308 
different conditions of inoculum preparation, biofilm growth and biofilm assessment for each 309 
microorganism. Major differences in the inoculum preparation and biofilm growth 310 
parameters, are expected as the parameters of these steps are largely dictated by the 311 
physiology of the microorganism being investigated and the type of experiment being 312 
performed. However, table 3 shows that large differences are also present among the biofilm 313 
assessment parameters such as dye concentrations and absorbance wavelengths. Taken 314 
together, this information means that comparing different datasets at this stage is not possible 315 
for different studies and that the guidelines can only facilitate reproducibility and comparison 316 
to a certain degree. On the other hand, it is important to note that the variability in protocols 317 
used in the biofilm area is often due to the differences in the subject of the investigations. 318 
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Hence, a consensus regarding certain aspects of the methodology is necessary to improve 319 
reproducibility. On this matter, there are already standardised biofilm methods approved by 320 
the American Society for Testing and Materials (ASTM) which could serve as a starting point 321 
for this process, such as the E2647-08 Standard Test Method for Quantification of a 322 
Pseudomonas aeruginosa Biofilm Grown Using a Drip Flow Biofilm Reactor with Low 323 
Shear and Continuous Flow24, the E2562-17 Standard Test Method for Quantification of 324 
Pseudomonas aeruginosa Biofilm Grown with High Shear and Continuous Flow using CDC 325 
Biofilm Reactor25 and the E2799-17 Standard Test Method for Testing Disinfectant Efficacy 326 
against Pseudomonas aeruginosa Biofilm using the MBEC Assay. 26 They can also provide 327 
an excellent example on how to identify critical steps and describe the methodology in order 328 
to ensure reproducibility.  329 
In addition, many investigations aim at optimising and modifying spectrophotometric and 330 
fluorometric methods to increase their efficiency, reliability and their applications. For 331 
example, Skogman et al proposed the use of consecutive staining with resazurin, WGA and 332 
crystal violet to improve the assessment of antimicrobial effectivity against biofilms.17 More 333 
recently, Junka et al, developed a way to assess wound dressing effectiveness in 24-well 334 
plates using crystal violet and TTC analysis.27 This means that with time, as new steps are 335 
introduced or more robust ways of performing certain steps are developed, the methods will 336 
evolve. Minimum information guidelines have the advantage of remaining applicable to the 337 
methods despite these changes.  338 
As science evolves, we will be able to measure new parameters and conditions which affect 339 
reproducibility. For example, even when manufactured from the same base polymer, 340 
microplates can have different surface properties depending on the production process, 341 
resulting in differences in cell adhesion. 28  As the methods to characterise surface properties 342 
become more accessible, parameters such as surface roughness might be used in future. Since 343 
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guidelines are often part of an online database such as MIBBI, they can be updated when 344 
necessary and evolve together with the methods.   345 
As is the case with compliance to MIABiE and other guidelines, compliance to the new 346 
guideline presented here will be difficult as it needs to be endorsed by both authors and 347 
journals.29,30 To improve compliance a balance needs to be obtained between the level of 348 
detail asked, and the ability of most labs to be able to provide such data. As an example, 349 
many studies have shown that oxygen availability influences biofilm formation and can lead 350 
to different physiological features being expressed.31 Therefore, understanding the oxygen 351 
availability within a well and across different wells in a microplate might be useful. However, 352 
most laboratories lack the kind of system needed to assess this environmental parameter and 353 
it would be very difficult to implement this reading routinely. Hence, the oxygen profile 354 
within the microplate is not a requirement in the guideline.  355 
We are convinced that the implementation of minimum information guidelines will 356 
contribute to solving the reproducibility crisis and thus improve the use that the research 357 
community makes of data and ultimately advance science.  358 
Methodology 359 
To create the minimum information guideline, we conducted a literature review using three 360 
different databases: Pubmed, Google Scholar and Web of Science. The research was 361 
separated into literature related to the methods and literature related to biofilm properties and 362 
the various factors affecting them. For the former, very broad search terms such as, “Biofilm 363 
AND microtit* plate”, “Biofilm AND Spectro*” and “Biofilm AND Fluor*” were used as a 364 
starting point. These resulted in thousands of hits from all three databases, and to further 365 
refine this output more specific terms such as “Crystal violet”, “Resazurin Or Alamar Blue”, 366 
“XTT”, “TTC”, “MTT”, “FDA”, “Syto9” and “WGA” were used. The results were ordered 367 
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according to number of citations (most to least) and publishing date (newest to oldest). 180 368 
papers were selected to be used as references to write the guideline. These were categorised 369 
into papers evaluating the methods and highlighting critical factors or steps, and papers that 370 
used the method in a specific investigation. The latter were used to create an understanding of 371 
what is commonly reported in scientific articles. Approximately 30 of the papers in this 372 
category were discarded from the literature review, as the only description of the method was 373 
a reference to a previously published paper.  374 
When researching the literature on biofilm properties and what affects them, terms such as 375 
“impact”, “influence”, “effect or affect”, “changes or differences” were used. These helped in 376 
creating an understanding of the different parameters that should be reported for a biofilm 377 
experiment. Additionally, other minimum information guidelines were used as templates in 378 
the initial drafting process.  379 
The final guidelines are the result of a dialog among biofilm experts familiar with microplate 380 
methods.  These experts are included in the authors list and contributed throughout the 381 
drafting process of the manuscript.  382 
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Figure Legends  552 
 553 
Figure 1. Schematic diagram of the guideline and critical steps for spectrophotometric 554 
and fluorometric methods of biofilm assessment. Schematic diagram of the different 555 
sections of this guideline, highlighting the various critical steps that can increase variability in 556 
biofilm experiments. Different approaches to washing were illustrated to showcase how 557 
variable these can be in different protocols. (Illustration courtesy of Story Jill)  558 
Figure 2. Show the dots on plots: scatter graphs allow readers to evaluate data 559 
distributions for themselves. Biofilm formation was measured for Pseudomonas aeruginosa 560 
strains CF39S and CF39, which express functional and mutant alleles of the thermosensory 561 
diguanylate cyclase (tdcA+ and tdcA-), respectively. Each condition has 48 replicates, 562 
representing sixteen technical replicates from each of three independent biological replicates. 563 
(a) Line graph. Datum points represent means and standard deviations. (b) Scatter plot. Each 564 
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point denotes a replicate datum point and lines and bars represent means and standard 565 
deviations, respectively. (Data courtesy of Joe J. Harrison). 566 
Tables  567 
Table 1. Common omissions in reporting spectrophotometric and fluorometric methods 568 
of biofilm assessment 569 
 570 
Omission Impact 
References  Often papers cited as containing the 
protocol followed in the study do not 
describe the full protocol and redirect you 
to another paper. This can create confusion 
when trying to understand the protocol that 
was followed.   
Replicates  The number of replicates within one 
experiment is not reported in the published 
paper. Furthermore, there are 
inconsistencies in the terminology used 
when describing replicates. For example, 
biological and technical replicates vs day-
to-day and within experiment replicates.  
Controls  While controls are mostly mentioned in the 
published articles, their values and 
variation are usually not reported. This 
makes it difficult to understand the 
variability associated with the method and 
how the raw data was processed.   
Inoculum preparation  Different culturing methods can affect the 
behaviour of microorganisms, their ability 
to attach to a surface, formation of 
aggregates, and response to different 
stimuli, chemicals, or other 
microorganisms.32 
Environmental factors In dry conditions, the microplate wells 
easily dry out, which affects biofilm 
formation. Hence, investigators take 
certain measures to avoid the problem 
which are usually not reported in the 
methodology section.  
Position of samples in the wells The layout of plates is often not reported, 
but the position of samples in the 
microplate can affect the results. For 
example, the “edge effect” is a suspected 
phenomenon which might be due to 
differences in evaporation between the 
outer and inner wells, as well as thermal 
changes in the plate.  
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Orbital shaker settings Most papers only refer to the rpm settings 
on their orbital shaker and omit other 
details such as the orbital diameter which 
can affect the shear stress exerted in the 
wells.33 
Washing  Description of this step is often omitted or 
vague terms such as, “gently rinse” or 
“slowly tip over plate” are used, which 
leave it up to the reader to determine how 
to perform the step.11,34 
Drying  This step is very often omitted altogether 
from the method description or contains 
very little detail on how it was performed.  
Raw data  Most articles do not provide their raw data 
and omit information on how this was 
analysed.35 
Outliers  Outliers are very often not included in the 
paper or, if reported, their exclusion is 
simply mentioned with little argumentation 
for it and how the final data analysis was 
affected by their removal.  
Data presentation 
 
 
  
The most common way of presenting 
microplate experiment data is through bar 
charts. However, often they do not provide 
all the relevant information from a dataset 
(distribution, outliers, paired data 
relations). Hence the way data is presented 
can limit its interpretation. Changing to a 
scatter plot or a box plot can provide more 
details for the same dataset. 19  
 571 
Table 2. Simplified checklist for minimum information guideline spectrophotometric 572 
methods of biofilm assessment  573 
01. Experimental design  
Aim of the experiment/hypothesis presented 
 
Type of experiment  
Biological and technical replicates   
Control replicates and descriptions  
Reference to original article containing protocol (If applicable)    
Supplementary information (If applicable)   
02. Biofilm formation 
Microorganism description  
Inoculum preparation protocol  
Treatment description (If applicable)   
Microplate description    
Plate layout i.e. sample distribution (Optional)   
Incubation conditions for microplate  
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03. Biofilm assessment method 
Planktonic suspension removal   
Washing description  
Staining description   
Additional steps: fixing, drying, buffer solutions (if applicable)  
Absorbance / Fluorescence measurement   
04. Statistical assessment and data interpretation 
Raw data handling  
Outliers  
Normality testing   
Appropriate data presentation  
Statistical test with post-hoc and descriptive stats   
Statistical programme used  
05. Bioinformatics (Optional)  
Standardised terminology  
Data formatting according to data submission guidelines   
Submission to online database   
 574 
 575 
  
Condition  
Organism  
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 Table 3. Example of the variability in protocol conditions of crystal violet assays for 576 
three different example microorganisms 577 
Staphylococcus aureus 
spp. 
Pseudomonas 
aeruginosa spp.   
Candida albicans  
Inoculum preparation    
Media TSB, TSB wS*, LBb**, 
Water 8,11,18,36–41 
TSB, TSB wS*, LBb**, 
LB**, BHI**, MHI**, 
T-broth**, AB* 8,42–49 
YNB**, YPD**, 
RPMI-1640**, 
SDB** 8,50–57  
Inoculum incubation 
temperature (°C) 
35-37 8,11,18,36–41 25-37 8,42–49 30-37 8,50–57 
Incubation time (hours) 0***-24 8,11,18,36–41 0***-24 8,42–49 12-24 8,50–57 
Inoculum shaking 
conditions   
0-200 rpm/min 8,11,18,36–
41
 
0-250 rpm/min 8,42–49 0-200 rpm/min, 
Roller drum 8,50–57 
Inoculum concentration / 
OD / growth phase at 
harvest   
103-108 CFU/mL, 0.5 
McFarland, 
OD600nm=0.1 8,11,18,36–41 
10-108 CFU/mL, 
OD600nm=0.0025, 
OD595=1.5 8,42–49 
104-108 CFU/mL,  
OD600nm=1 8,50–57  
Biofilm growth    
Media TSB, LB**, BHI** 
8,11,18,36–41
 
TSB, T-broth**, AB**, 
BHI**, MHI** 8,42–49 
YNB**, YPD**, 
RPMI-1640**, 
ASM**, SDB**, 
PBS**** 8,50–57 
Incubation temperature (°C) 35-37 8,11,18,36–41 25-37 8,42–49 37 8,50–57 
Incubation time (hours) 18-48 8,11,18,36–41 2-48 8,42–49 2-48 8,50–57 
Shaking conditions 0-200 rpm/min 8,11,18,36–
41
 
0-180 rpm/min 8,42–49 0-120 rpm/min 
8,50–57
 
Biofilm Assessment    
Washing agent Water, Saline, 
PBS****, MilliQ water 
8,11,18,36–41
 
Saline, Water, PBS*** 
8,42–49
 
PBS****, Water, 
Saline 8,50–57 
Washing (x times) 1-3 8,11,18,36–41 1-3 8,42–49 1-3 8,50–57 
Crystal violet concentration 0.01-2.3 % 8,11,18,36–41 0.1-2 % 8,42–49 0.02-1 % 8,50–57 
Staining time 1-20 min 8,11,18,36–41 5-30 min 8,42–49 5-45 min 8,50–57 
Solubilisation agent 33 % acetic acid, 95-
100 % ethanol 8,11,18,36–
41
 
30-33 % acetic acid, 95-
100 % ethanol, 
DMSO**** 8,42–49 
30-33% acetic 
acid, 95 % 
ethanol, 0.1% 
Triton-X 8,50–57 
Absorbance wavelength 
(nm) 
540-595 8,11,18,36–41 550-595 8,42–49 540-595 8,50–57 
*wS – with Supplement (i.e. added yeast and/or glucose)  
**TSB- Tryptic Soy Broth; LBb – Luria Bertani broth; BHI- Brain Heart Infusion; LB – Lysogeny 
broth; MHI – Mueller-Hinton broth; T-broth – Terrific broth; AB – minimal growth media; YNB – 
Yeast Nitrogen Base; YPD – Yeast Peptone Dextrose; SDB – Sabauraund Dextrose Broth; RPMI-1640 
- Roswell Park Memorial Institute–1640 medium; ASM – Artificial Saliva Medium;  
***0 – Inoculum prepared directly from agar culture  
****PBS- Phosphate buffered saline; DMSO – Dimethyl sulfoxide  
Table 1. Common omissions in reporting spectrophotometric and fluorometric methods 
of biofilm assessment 
 
Omission Impact 
References  Often papers cited as containing the 
protocol followed in the study do not 
describe the full protocol and redirect you 
to another paper. This can create confusion 
when trying to understand the protocol that 
was followed.   
Replicates  The number of replicates within one 
experiment is not reported in the published 
paper. Furthermore, there are 
inconsistencies in the terminology used 
when describing replicates. For example, 
biological and technical replicates vs day-
to-day and within experiment.  
Controls  While controls are mostly mentioned in the 
published articles, their values are usually 
not reported. This makes it difficult to 
understand the variability associated with 
the method and how the raw data was 
processed.   
Inoculum preparation  Different culturing methods can affect the 
behaviour of microorganisms, their ability 
to attach to a surface, formation of 
aggregates, and response to different 
stimuli, chemicals, or other 
microorganisms.28 
Environmental factors In dry conditions, the microtiter plate wells 
easily dry out, which affects biofilm 
formation. Hence, investigators take 
certain measures to avoid the problem 
which are usually not addressed in the 
methodology section.  
Position of samples in the wells The layout of plates is often not reported, 
but the position of samples in the 
microtiter plate can affect the results. This 
is due to the fact that humidity and air 
distribution can differ in the inner wells 
compared to the outer ones, thus resulting 
in differences in biofilm formation.29 
Orbital shaker settings Most papers only refer to the rpm settings 
on their orbital shaker and omit other 
details such as the orbital diameter which 
can affect the shear stress exerted in the 
wells.30 
Washing  Description of this step is often omitted or 
vague terms such as, “gently rinse” or 
“slowly tip over plate” are used, which 
leave it up to the reader to determine how 
to perform the step.10,31 
Drying  This step is very often omitted altogether 
from the method description or contains 
very little detail on how it was performed.  
Raw data  Most articles do not provide their raw data 
and omit information on how this was 
analysed.32 
Outliers  Outliers are very often not included in the 
paper or, if reported, their exclusion is 
simply mentioned with little argumentation 
for it and how the final data analysis was 
affected by their removal.  
 
Table 2. Simplified checklist for minimum information guideline spectrophotometric 
methods of biofilm assessment  
01. Experimental design  
Aim of the experiment/hypothesis presented  
Type of experiment  
Biological and technical replicates   
Positive and negative control replicates and description  
Reference to original article containing protocol (If applicable)    
Supplementary information (If applicable)   
02. Biofilm forming method 
Microorganism description  
Inoculum preparation protocol  
Treatment description (If applicable)   
Microtiter plate description    
Plate layout i.e. sample distribution (Optional)   
Incubation conditions for microtiter plate  
03. Biofilm assessment method 
Planktonic suspension removal   
Washing description  
Staining description   
Additional steps: fixing, drying, buffer solutions (if applicable)  
Absorbance / Fluorescence measurement   
04. Statistical assessment and data interpretation 
Raw data handling  
Outliers  
Normality testing   
Appropriate data presentation  
Statistical test with post-hoc and descriptive stats   
Statistical programme used  
05. Bioinformatics (Optional)  
Standardised terminology  
Data formatting according to data submission guidelines   
Submission to online database   
 
 
Table 3. Example of the variability in protocol conditions of crystal violet assays for 
three different example microorganisms 
 
  
Condition  
Organism  
Staphylococcus aureus 
spp. 
Pseudomonas 
aeruginosa spp.   
Candida albicans  
Inoculum preparation    
Media TSB, TSB wS*, LBb**, 
Water 7,10,17,33–38 
TSB, TSB wS*, LBb**, 
LB**, BHI**, MHI**, 
T-broth**, AB* 7,39–46 
YNB**, YPD**, 
RPMI-1640**, 
SDB** 7,47–54  
Inoculum incubation 
temperature (°C) 
35-37 7,10,17,33–38 25-37 7,39–46 30-37 7,47–54 
Incubation time (hours) 0***-24 7,10,17,33–38 0***-24 7,39–46 12-24 7,47–54 
Inoculum shaking 
conditions   
0-200 rpm/min 7,10,17,33–
38 
0-250 rpm/min 7,39–46 0-200 rpm/min, 
Roller drum 7,47–54 
Inoculum concentration / 
OD / growth phase at 
harvest   
103-108 CFU/mL, 0.5 
McFarland, 
OD600nm=0.1 7,10,17,33–38 
10-108 CFU/mL, 
OD600nm=0.0025, 
OD595=1.5 7,39–46 
104-108 CFU/mL,  
OD600nm=1 7,47–54  
Biofilm growth    
Media TSB, LB**, BHI** 
7,10,17,33–38 
TSB, T-broth**, AB**, 
BHI**, MHI** 7,39–46 
YNB**, YPD**, 
RPMI-1640**, 
ASM**, SDB**, 
PBS**** 7,47–54 
Incubation temperature (°C) 35-37 7,10,17,33–38 25-37 7,39–46 37 7,47–54 
Incubation time (hours) 18-48 7,10,17,33–38 2-48 7,39–46 2-48 7,47–54 
Shaking conditions 0-200 rpm/min 7,10,17,33–
38 
0-180 rpm/min 7,39–46 0-120 rpm/min 
7,47–54 
Biofilm Assessment    
Washing agent Water, Saline, 
PBS****, MilliQ water 
7,10,17,33–38 
Saline, Water, PBS*** 
7,39–46 
PBS****, Water, 
Saline 7,47–54 
Washing (x times) 1-3 7,10,17,33–38 1-3 7,39–46 1-3 7,47–54 
Crystal violet concentration 0.01-2.3 % 7,10,17,33–38 0.1-2 % 7,39–46 0.02-1 % 7,47–54 
Staining time 1-20 min 7,10,17,33–38 5-30 min 7,39–46 5-45 min 7,47–54 
Solubilisation agent 33 % acetic acid, 95-
100 % ethanol 7,10,17,33–
38 
30-33 % acetic acid, 95-
100 % ethanol, 
DMSO**** 7,39–46 
30-33% acetic 
acid, 95 % 
ethanol, 0.1% 
Triton-X 7,47–54 
Absorbance wavelength 
(nm) 
540-595 7,10,17,33–38 550-595 7,39–46 540-595 7,47–54 
*wS – with Supplement i.e. added yeast and/or glucose  
**TSB- Tryptic Soy Broth; LBb – Luria Bertani broth; BHI- Brain Heart Infusion; LB – Lysogeny 
broth; MHI – Mueller-Hinton broth; T-broth – Terrific broth; AB – minimal growth media; YNB – 
Yeast Nitrogen Base; YPD – Yeast Peptone Dextrose; SDB – Sabauraund Dextrose Broth; RPMI-1640 
- Roswell Park Memorial Institute–1640 medium; ASM – Artificial Saliva Medium;  
***0 – Inoculum prepared directly from agar culture 
****PBS- Phosphate buffered saline; DMSO – Dimethyl sulfoxide  


